The prognostic impact of revascularization strategy in acute myocardial infarction and cardiogenic shock: Insights from the British Columbia Cardiac Registry. Issue 5 (26th April 2018)

• Record Type: Journal Article
• Authors: McNeice, Andrew; Nadra, Imad J.; Robinson, Simon D.; Fretz, Eric; Ding, Lillian; Fung, Anthony; Aymong, Eve; Chan, Albert W.; Hodge, Steven; Webb, John; Sheth, Tej; Jolly, Sanjit S.; Mehta, Shamir R.; Della Siega, Anthony; Wood, David A.; Iqbal, M. Bilal
• Is Part Of: Catheterization and cardiovascular interventions. Volume 92:Issue 5(2018)
• Page Start: E356
• Page End: E367
• Publication Date: 2018-04-26
• Subjects: AMI—acute myocardial infarction/STEMI -- CS—shock -- cardiogenic -- PCI—percutaneous coronary intervention; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.27648
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Background: In patients with acute myocardial infarction (AMI) and cardiogenic shock (CS), percutaneous coronary intervention (PCI) of the culprit vessel is associated with improved outcomes. A large majority of these patients have multivessel disease (MVD). Whether or not PCI of non‐culprit disease in the acute setting improves outcomes continues to be debated. We evaluated the prognostic impact of revascularization strategy for patients presenting with AMI and CS. Methods: We compared culprit vessel intervention (CVI) versus multivessel intervention in 649 patients with AMI, CS, and MVD enrolled in the British Columbia Cardiac Registry. We evaluated mortality at 30 days and 1 year. Results: CVI was associated with lower mortality at 30 days (23.7% vs. 34.5%, P = 0.004) and 1 year (32.6% vs. 44.3%, P = 0.003). CVI was an independent predictor for survival at 30 days (HR = 0.63, 95% CI: 0.45–0.88, P = 0.009) and 1 year (HR = 0.72, 95% CI: 0.54–0.96, P = 0.027). These findings were confirmed in propensity‐matched cohorts. Subgroup analyses indicated that CVI was associated with lower mortality in patients aged <80 years; non‐diabetics; and those presenting with ST‐elevation MI. When analyzing non‐culprit anatomy, PCI of non‐culprit LAD disease was associated with higher 1‐year mortality (HR = 1.51, 95% CI: 1.13–2.01, P = 0.006), primarily with non‐culprit proximal LAD disease (HR = 1.82, 95% CI: 1.20–2.76, P = 0.005). However, PCI of non‐culprit non‐proximal LAD, LCx, and RCA disease was not associated with mortality. Conclusions: In patients with AMI and CS, a strategy of CVI appears to be associated with lower mortality. These findings are consistent with recently published randomized‐controlled trial data.